NCT07095868View on ClinicalTrials.gov

Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

November 30, 2029

Study Completion Date

November 30, 2031

Conditions

Selected Types of Solid Tumor

Interventions

BIOLOGICAL

EVM14

Cancer Vaccine

COMBINATION_PRODUCT

Pembrolizumab

Anti-PD1 antibody

Trial Locations (7)

10022

Memorial Sloan Kettering Cancer Center, New York

22031

NEXT Oncology, Fairfax

77030

MD Anderson Cancer Center, Houston

200030

Shanghai Chest Hospital, Shanghai

210000

Nanjing Drum Tower Hospital, Nanjing

210029

The First Affiliated Hospital With Nanjing Medical University, Nanjing

410006

Hunan Cancer Hospital, Changsha

All Listed Sponsors

lead

Everest Medicines (Beijing) Co., Ltd.

INDUSTRY

NCT07095868 - Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors | Biotech Hunter | Biotech Hunter